Recurrences after surgical resection of intraductal papillary mucinous neoplasm of the pancreas: A single-center study of recurrence predictive factors

Pancreas

Volumn 41, Issue 1, 2012, Pages 137-141

  Passot, Guillaume ^a   Lebeau, Roger ^a   Hervieu, Valérie ^a   Ponchon, Thierry ^a,b   Pilleul, Franck ^a,b   Adham, Mustapha ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

intraductal papillary mucinous neoplasm; recurrence; surgery

Indexed keywords

ADULT; AGED; AMERICAN SOCIETY OF ANESTHESIOLOGIST SCORE; ARTICLE; CANCER INVASION; CENTRAL PANCREATECTOMY; CORRELATION ANALYSIS; DISEASE SEVERITY; DISTANT METASTASIS; DYSPLASIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; ISTAL PANCREATECTOMY; MAJOR CLINICAL STUDY; MALE; PANCREAS RESECTION; PANCREAS SURGERY; PANCREATICODUODENECTOMY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REOPERATION; RISK ASSESSMENT; SCORING SYSTEM; TUMOR RECURRENCE;

ADENOCARCINOMA, MUCINOUS; AGED; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84655169822     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318222bc9c     Document Type: Article

References (29)

1. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6(1-2):17-32.
2. Tanaka M, Kobayashi K, Mizumoto K, et al. Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J. Gastroenterol. 2005;40(7):669-675. (Pubitemid 41349077)
3. Doi R, Fujimoto K, Wada M, et al. Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery. 2002;132(1):80-85. (Pubitemid 34787825)
4. Sugiyama M, Izumisato Y, Abe N, et al. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J. Surg. 2003;90(10):1244-1249. (Pubitemid 37330429)
5. Salvia R, Fernandez-Del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: Clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239(5):678-685; discussion 85-87.
6. Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002;123(5):1500-1507. (Pubitemid 35231650)
7. Loftus EV Jr, Olivares-Pakzad BA, Batts KP, et al. Intraductal papillary-mucinous tumors of the pancreas: Clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic. Gastroenterology. 1996;110(6):1909-1918.
8. Couvelard A, SauVanet A, Kianmanesh R, et al. Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: A prospective evaluation. Ann Surg. 2005;242(6):774-778, discussion 8-80.
9. Nara S, Shimada K, Sakamoto Y, et al. Clinical significance of frozen section analysis during resection of intraductal papillary mucinous neoplasm: should a positive pancreatic margin for adenoma or borderline lesion be resected additionally? J. Am Coll Surg. 2009;209(5):614-621.
10. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: An updated experience. Ann Surg. 2004;239(6):788-797; discussion 97-9.
11. Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143(7):639-646; discussion 46. (Pubitemid 352040228)
12. Wada K, Kozarek RA, Traverso LW. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J. Surg. 2005;189(5):632-636; discussion 7.
13. Matsumoto T, Aramaki M, Yada K, et al. Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. J. Clin Gastroenterol. 2003;36(3):261-265. (Pubitemid 36232639)
14. Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J. Surg Pathol. 2000;24(10):1372-1377.
15. Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasmYassociated invasive adenocarcinoma of the pancreas. Ann Surg. 2010;251(3):470-476.
16. Bernard P, Scoazec JY, Joubert M, et al. Intraductal papillary-mucinous tumors of the pancreas: Predictive criteria of malignancy according to pathological examination of 53 cases. Arch Surg. 2002;137(11):1274-1278. (Pubitemid 35345902)
17. Nagai K, Doi R, Ito T, et al. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J. Hepatobiliary Pancreat Surg. 2009;16(3):353-358.
18. Tang RS, Weinberg B, Dawson DW, et al. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol. 2008; 6(7):815-819; quiz 719. (Pubitemid 351888940)
19. Pelaez-Luna M, Chari ST, Smyrk TC, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J. Gastroenterol. 2007;102(8):1759-1764. (Pubitemid 47206677)
20. Huang ES, Gazelle GS, Hur C. Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: A cost-effectiveness analysis. Dig Dis Sci. 2010;55(3):852-860.
21. Shin SH, Han DJ, Park KT, et al. Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J. Surg. 2010;34(4):776-783.
22. Kanno A, Satoh K, Hirota M, et al. Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. J. Gastroenterol. 2010;45(9):952-959.
23. Sai JK, Suyama M, Kubokawa Y, et al. Pancreatic-duct-lavage cytology in candidates for surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas: should the International Consensus Guidelines be revised? Gastrointest Endosc. 2009;69(3 Pt 1):434-440.
24. Bassi C, Sarr MG, Lillemoe KD, et al. Natural history of intraductal papillary mucinous neoplasms (IPMN): Current evidence and implications for management. J. Gastrointest Surg. 2008;12(4):645-650.
25. Fujii T, Kato K, Kodera Y, et al. Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery. 2010;148(2):285-290.
26. Paye F, SauVanet A, Terris B, et al. Intraductal papillary mucinous tumors of the pancreas: Pancreatic resections guided by preoperative morphological assessment and intraoperative frozen section examination. Surgery. 2000;127(5):536-544. (Pubitemid 30257512)
27. Nagai E, Ueki T, Chijiiwa K, et al. Intraductal papillary mucinous neoplasms of the pancreas associated with so-called ïïmucinous ductal ectasiaïï. Histochemical and immunohistochemical analysis of 29 cases. Am J. Surg Pathol. 1995;19(5):576-589.
28. Ikeuchi N, Itoi T, Sofuni A, et al. Prognosis of cancer with branch duct type IPMNof the pancreas.World J. Gastroenterol. 2010;16(15):1890-1895.
29. Reddy S, Wolfgang CL, Cameron JL, et al. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Ann Surg. 2009;250(2):282-287.